Both bone marrow and solid organ transplants (SOTs) can be life saving for a wide variety of diseases. We reviewed the literature and summarized the experiences of dual transplants. In total, 37 patients received a SOT for organ failure after a previous hematopoietic stem cell transplant. In all, 12 subjects received SOTs followed by a bone marrow transplant, while three patients received simultaneous SOTs and bone marrow transplants. Of these 52 patients, 37 were alive at the time of the original report at follow-up times ranging from 3 months to 8 years. A special registry for data collection may prove helpful for obtaining long-term follow-up data and providing outcome information that may improve future patient survival.
1
Both marrow and organ transplants can save thousands of lives. Prolonged administration of immunosuppressive agents for prevention of graft-versus-host disease (GVHD) and graft rejection results in delayed immune reconstitution, opportunistic infections, and the occurrence of lymphoproliferative disorders. Research efforts to improve immunologic tolerance in SOTs using the same donor with marrow augmentation have been reported in animal models as well as human clinical trials. [2] [3] [4] [5] [6] The mechanism(s) of tolerance induction, with simultaneous BMT and SOT is however, beyond the scope of this review.
Methods
To assess the success of rescuing patients who experienced organ failure from a prior transplant using a subsequent transplant, we conducted a comprehensive MEDLINE search. We reviewed all articles from 1980 to the present that reported dual BMTs and SOTs. Search terms included bone marrow, renal, liver, lung, and cardiac transplantation, GVHD, and graft rejection. The references of all pertinent studies and review articles, including a review by Dey et al, 7 were scanned for studies missed via MEDLINE. We attempted to exclude overlap between cases reported separately that also were included in full-length articles.
Patients receiving SOT for organ failure following previous bone marrow transplant A total of 37 patients reported in the literature received SOTs for organ failure after an initial bone marrow transplant.
Renal transplant following marrow transplant (Table 1) Bone marrow transplant nephropathy is a well-described syndrome whose etiologic factors may include total body irradiation, cytotoxic therapy, or nephrotoxic agents used during supportive care. 8 A recent, retrospective analysis of marrow transplant nephropathy by Kist-van Holthe et al. 9 examined the glomerular filtration rate in a total of 142 children who underwent allogeneic bone marrow transplantation. In all, 34% developed acute renal insufficiency defined by doubling of creatinine in the first 3 months. At 1 year, 28% of children had chronic renal insufficiency. Of the patients, 10% required dialysis after BMT, and this has been associated with high mortality in both adults and children. [10] [11] [12] their original BMT. [12] [13] [14] [15] [16] [17] [18] Nine patients received the kidney graft from the original bone marrow donor. Of these nine donors, six were six of six HLA-matched relatives (sibling), two were four of six matched relatives (sister and mother), and the other donor a haploidentical father (degree of matching not reported). All nine patients were reported to be alive and well without evidence of rejection. Seven patients were off all immunosuppressants at the time of their case reports (3-30 months) and four were never given immunosuppressants after kidney engraftment. One episode of mild rejection, 14 however, was observed in the recipient whose donor was the partially matched mother. Three patients (whose grafts were from two cadaveric and one living unrelated donor) remained on immunosuppressants 16 months to 2.2 years after the kidney graft. One death was reported because of metastatic squamous cell carcinoma of the vagina 12 months postrenal transplant. 16 With reported follow-up between 3 months and 6 years, 12 of 13 patients who received a kidney graft after an initial bone marrow transplant survived.
Liver transplant following marrow transplant (Table 2)
Liver damage in the form of veno-occlusive disease (VOD) occurs after both autologous and allogeneic BMT and is associated with high mortality. 19 Effective therapy for VOD has remained a clinical challenge for the past decade. The first report of liver transplantation for VOD after BMT was in 1990. 20 Since then, a total of 14 liver transplants have been published (Table 2) . [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Of them, five liver transplants were performed for GVHD (104 days-11 months after BMT) and the remainder were for hepatic VOD (35-79 days after BMT). Only one patient received a living related (mother) left segment liver transplant, 26 while the other 13 subjects all received orthotopic liver grafts. One patient received two liver transplants 18 days apart. 25 Since the liver donors were usually third party in origin, immunosuppressive agents such as prednisone and cyclosporine were administered and maintained to prevent liver graft rejection. One interesting observation in this subgroup of patients was that a few individuals developed clinical GVHD caused by liver-derived T cells; in addition, microchimerism because of donor liver cells was detected within the marrow microenvironment for several years. 24 Six of 14 patients were alive at the time of the reports; all required continued immunosuppressive agent therapy to prevent rejection. The survival for liver transplant in BMT patients may be hampered by the fact that VOD usually occurs early in the BMT recovery phase. Furthermore, unlike hemodialysis that can be used to support renal failure while kidney allografts are being sought, there is no such possible intervention in liver failure. The combination of difficulties in quickly locating a donor and performing a transplant in a 'sicker' patient likely contributes to the increased morbidity and mortality associated with the liver transplant in this subpopulation.
Lung transplant following marrow transplant (Table 3) Like other organ systems, pulmonary pathology during BMT can be caused by various etiologies at different phases of BMT recovery. 31 Pulmonary edema, diffuse alveolar hemorrhage, drug reaction, and engraftment syndrome are some of the complications before or around the time of engraftment. Radiation or chemotherapy-induced pneumonitis can also occur at a later time. Pulmonary decompensation owing to infectious etiologies (bacterial, viral, or fungal) carries a high mortality throughout the first year of BMT. Chronic GVHD (bronchiolitis obliterans) with obstructive lung disease often progresses despite aggressive medical interventions. Lung transplantation may offer a promising curative option to patients with refractory chronic pulmonary failure. Calhoon et al 32 reported the first lung transplantation following a prior BMT; since then, a total of nine lung transplantations have been reported for similar conditions. [33] [34] [35] [36] All of the underlying causes were GVHD except two (lung fibrosis and radiation pneumonitis). Six patients were children while the other three were 25, 27, and 37 years of age. All except one 34 received cadaveric lungs (three with single and five with double). The patient who received one lobe from his marrow donor (mother) was weaned off immunosuppressive agents by 16 weeks and was doing well at 14 months postlung transplant. Two patients 32 (author's own experience) received two bone marrow transplants from the same donor for their diseases; both of them were alive after cadaveric lung transplants. Overall, two-thirds of the patients were reported to be alive between 9 months and 6 years follow-up.
Cardiac transplant following marrow transplant (Table 3) Cardiac toxicities post BMT could be because of the underlying disease (such as thalassemia 38 ), previous chemotherapy (such as anthracycline 39 ) or BMT process (such as cyclophosphamide 40 ). Studies in both adults and children, however, have shown that life-threatening cardiac events are a rare occurrence after BMT. 41, 42 On the other hand, there are no reliable factors to predict such a situation arising in an individual patient. There has been only a single case report describing an orthotopic cardiac transplant for cardiomyopathy 12 months after a sibling-matched donor BMT. 39 The patient remained stable at 1-year follow-up while receiving immunosuppressants.
Patients receiving bone marrow transplant for hematologic malignancy or nonmalignant hematologic abnormalities after previous solid organ transplant
In all, 12 patients have been reported who have received a marrow transplant for malignant and nonmalignant hematologic abnormalities after an initial solid organ transplant (Table 4) .
Marrow transplant following liver transplant
The development of aplastic anemia after viral hepatitis has been well documented. 43 Sibling-matched donor BMT is the treatment of choice for newly diagnosed aplastic anemia and is associated with a reported survival rate of Combined hematopoietic stem cell and solid organ transplants Follow-up time is reported from bone marrow transplant. AML, acute myeloid leukemia; ATG, antithymocyte globulin; AUTO,autologous; Aza, azathioprine; BEAM, BCNU, Ara-C, etoposide, and melphalan; BU, busulfan; CAH, chronic active hepatitis; CMV, cytomegalovirus; CHOP, cyclophosphamide, adriamycin, oncovin, and prednisone; CSA, cyclosporin A; CY, cyclophosphamide; FK, tacrolimus; GS, glomerulosclerosis; GVHD, graft-versus-host disease; MDS, myelodysplasia; HLH, hemophagocytic lymphohistiocytosis; MMF, mycophenolate mofetil; MTX, methotrexate; NA, non-A; NB, non-B; NC, non-C; Pred, prednisone; SAA, severe aplastic anemia; SOT, solid organ transplant; TBI, total body irradiation; TLI, total lymphoid irradiation; VP, etoposide; VOD, veno-occlusive disease.
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. 44 Liver transplantation is the treatment of choice for fulminant hepatic failure. 45 Aplastic anemia, however, can also develop in patients after liver transplant performed for viral hepatitis. 46 Aplastic anemia arising in this situation has been attributed to the underlying viral process, since it has not been reported to occur after liver transplantation for other indications. 47 Seven patients (five children and two adults) have been reported in the literature who received BMT between 2 and 44 months after their liver transplant. The initial indications for liver transplantation were hepatitis (n ¼ 6) and acute hepatic failure (n ¼ 1). All but one patient received an orthotopic liver graft. One child, who received the liver graft from her mother, developed hemophagocytic lymphohistocytosis 2 months post-transplant. This patient subsequently received the marrow graft from the same donor (mother) and was weaned off immunosuppressants. 53 Another patient developed lymphoma 52 and subsequently received an autologous BMT; the patient continues to receive immunosuppressants. The other five patients received bone marrow grafts from HLA-matched siblings. All seven patients received myeloablative conditioning regimens prior to BMT and were alive at 4 months to 8 years post-BMT. The report of the patient with the longest follow-up 54 demonstrates the importance of close monitoring in the post-transplant immunocompromised phase. This patient developed renal cell carcinoma and mucoepidermoid carcinoma of the parotid gland at 8 months and 6 years post-BMT, respectively.
Marrow transplant following renal transplant
Four patients developed hematologic malignancies (three leukemia and one lymphoma) and received bone marrow transplant (three allogeneic and one autologous) at 7-10 years after their kidney transplant. All four patients received myeloablative conditioning regimens prior to the marrow graft. Although two patients received kidney and marrow grafts from the same HLA-matched donor, all three allogeneic BMT patients developed GVHD. One patient died of lymphoma recurrence at 10 months, the other two died approximately on day 40 because of GVHD, hepatic VOD, or the combination.
Marrow transplant following cardiac transplant
One patient received orthotopic cardiac transplantation for viral cardiomyopathy and developed myelodysplasia with monosomy 7 ten years later.. He subsequently received a five out of six HLA-matched marrow graft from his brother and was reported to be well 7 months post-BMT.
Patients receiving simultaneous bone marrow and SOTs for their coexisting malignancy/organ failure (Table 5) There are three unique clinical situations that can present a great therapeutic challenge to healthcare professionals: (1) a patient who presents with both primary disease and metastasis to a solid organ, (2) someone in whom the primary disease also may induce permanent visceral organ failure in the absence of metastasis, and (3) two independent disease processes involving different organs. Three reports illustrate approaches to these three different scenarios with favorable outcomes. Huber et al 60 performed an orthotopic liver transplant for a woman with breast cancer with liver metastasis. After 85 days, the patient underwent a bone marrow transplant using a previously cryopreserved autologous marrow graft after cyclophosphamide and total body irradiation. Spitzer et al 61 reported a combined HLA-matched donor bone marrow and kidney transplant simultaneously in a patient with multiple myeloma. They used a reduced-intensity preparative regimen with cyclophosphamide, thymic irradiation, and antithymocyte globulin. Immunosuppression was discontinued at day 73 without evidence of GVHD or rejection. In treating a patient with cholangiopathy and hyper-IgM syndrome, Hadzˇic´et al 62 first performed an orthotopic liver transplant followed by a HLA-matched unrelated donor bone marrow transplant 34 days later. Mild GVHD responsive to treatment was noted in this patient. All three patients were alive at the time of reports with 6-13 months follow-up.
Conclusions
A total of 52 cases were identified through the literature search and analyzed in this review. These data are Table 5 Bone marrow transplant and SOT for the co-existing malignanc years/organ failures In some patients who received an initial bone marrow transplant, then later a solid organ (kidney) transplant from the same donor, no or minimal immunosuppression was given to prevent organ rejection. Although rejection was observed, it usually responded to treatment. The reverse scenario, however, did not appear to be the case: patients who underwent a solid organ (kidney) transplant first still received immunosuppressant therapy for renal rejection prophylaxis. Liver transplantation is unique in that the graft may contain some immunocompetent cells that can cause either liver donor-induced GVHD in patients who received prior HLA-matched bone marrow transplant 24 or liver donor-induced tolerance in patients who had a liver transplant first. 43 Myeloablative preparative regimens were administrated to all the patients who had previous solid organ transplant prior to their bone marrow graft. There was no treatmentrelated mortality observed in all of the six liver and bone marrow dual transplant patients. Reduced-intensity, nonmyeloablative regimens may become an attractive approach to combining both SOTs and marrow transplants as reported by Spitzer et al. 61 Although rarely indicated, we can anticipate more patients may be treated with this modality in the future.
No case of post-transplant lymphoproliferative disorder was reported in these unique populations despite the use of prolonged immunosuppressive therapy in some patients. Two separate episodes of malignancy, however, were noted subsequently within an 8-year follow-up in one liver transplant patient and one renal transplant patient who developed cancer 12 months later. Long-term monitoring is essential for early detection of any late effects in these dualorgan transplant patients.
Finally, the accounts in the literature describing these dual transplants generally represent short-term results lacking long-term follow-up. Also, it is likely that there is a publication bias, that is, investigators tend to report favorable results. A special registry for data collection may be helpful for long-term follow-up and improvement in future patient survival.
Addendum: Since the completion of this manuscript, there have been three additional reports [63] [64] [65] of patients receiving both bone marrow and solid organ transplants, one in each category mentioned in this analysis. We may be seeing more growth in this exciting field.
